Paxalisib Combination Shows Early Responses in TNBC

Company: Kazia Therapeutics · Drug: Paxalisib · Combination: Paxalisib + Pembrolizumab + Chemotherapy · Indication: Metastatic Triple-Negative Breast Cancer · Date: August 27, 2026 Summary Kazia Therapeutics reported early efficacy signals from a small cohort of metastatic triple-negative breast cancer patients treated with paxalisib combined…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Ipsen Acquires Kartos Therapeutics for Up to $1.75B
Kuva Merger Collapse Forces Lisata Therapeutics Retrenchment
Gilead – $5B Tubulis Acquisition
Scribe Sets Terms for a $100 Million IPO